$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025 , to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J. , Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc . ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and... Read More

CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025 , the closing bid price of the Company's common stock was at $1.00 per share or greater, and accordingly, the Company... Read More

$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J. , June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its... Read More

$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J. , June 10, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered... Read More

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J. , June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that... Read More

CRANFORD, N.J. , May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal quarter ended March 31, 2025 . "As we continue to focus on the planned launch of our first FDA-approved product, LYMPHIR,... Read More

CEO Leonard Mazur to present on Thursday, June 5, 2025 , at 3:10 pm ET CRANFORD, N.J. , May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur , Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York... Read More

CRANFORD, N.J. , April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase... Read More

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024 . Fiscal First Quarter 2025 Business Highlights and Subsequent Developments... Read More

Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J. , Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (" Citius Pharma " or the "Company") ( Nasdaq : CTXR ) and its... Read More